Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer.

ABSTRACT:

Background

Dual-targeted therapy is currently the standard adjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) and lymph node-positive (LN+) breast cancer. However, the optimal therapeutic strategy for patients with HER2+ and lymph node-negative (LN-) breast cancer remains unclear. This population-based study aimed to explore the factors associated with survival in patients with HER2+ and LN- breast cancer, and develop a survival-predicting nomogram in the era of trastuzumab-based single-targeted therapy.

Methods

We collected the clinicopathological information of HER2+ and LN- breast cancer patients who underwent chemotherapy and surgery from The Surveillance, Epidemiology, and End Results (SEER) database (2010-2016, the Trastuzumab-based single

SUBMITTER: Shi Q 

PROVIDER: S-EPMC8340331 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature